Maali Milhem, MD
NPI 1003170416 · Endocrinology, Diabetes & Metabolism Physician · Munster, IN
Enrolled with Medicare as Practitioner - Endocrinology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1003170416
- Entity type
- Individual
- Primary specialty
- Endocrinology, Diabetes & Metabolism PhysicianAllopathic & Osteopathic Physicians
- Credential
- MD
- Sex
- Female
- Sole proprietor
- No
- License
- 01091478A (IN)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
13 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
50 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Hemoglobin A1c Level83036 | 50 | $9 |
Typical Medicare-allowed amounts for these services range $9–$9 (2024). The Medicare-allowed amount is what Medicare recognizes for a service under fee-for-service — a reference figure for 2024, not a price quote and not what you would be billed. Medicare Part B covers roughly an eighth of all NPIs (65+ skew); services with fewer than 11 beneficiaries are suppressed by CMS. Source: CMS Medicare Physician & Other Practitioners, by Provider & Service.
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 23 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Levothyroxine Sodium | 135 | 57 |
| Empagliflozinbrand: Jardiance | 75 | 31 |
| Metformin Hclbrand: Metformin Hcl Er | 70 | 43 |
| Semaglutidebrand: Ozempic | 52 | 23 |
| Metformin Hcl | 48 | 25 |
| Insulin Glargine,hum.rec.anlogbrand: Lantus Solostar | 41 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$454 across 23 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2012-06-29
- Last updated
- 2024-07-16
- Certified
- 2024-07-16
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.